HUSSEIN TAWBI to Neoplasm Metastasis
This is a "connection" page, showing publications HUSSEIN TAWBI has written about Neoplasm Metastasis.
Connection Strength
0.626
-
Matching wits with melanoma brain metastases: from biology to therapeutics. Clin Cancer Res. 2014 Nov 01; 20(21):5346-8.
Score: 0.239
-
The standard of care for brain metastases in melanoma. Clin Adv Hematol Oncol. 2020 Jan; 18(1):28-31.
Score: 0.087
-
Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. Cancer. 2020 02 01; 126(3):523-530.
Score: 0.086
-
New Era in the Management of Melanoma Brain Metastases. Am Soc Clin Oncol Educ Book. 2018 May 23; 38:741-750.
Score: 0.078
-
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nat Med. 2020 10; 26(10):1557-1563.
Score: 0.023
-
B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020 01; 577(7791):549-555.
Score: 0.022
-
Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. Cancer. 2019 Dec 01; 125(23):4193-4202.
Score: 0.021
-
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
Score: 0.019
-
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res. 2018 01 01; 24(1):22-32.
Score: 0.019
-
Melanoma Brain Metastases: Current Areas of Investigation and Future Directions. Cancer J. 2017 Jan/Feb; 23(1):68-74.
Score: 0.018
-
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015 Mar; 5(3):264-73.
Score: 0.015